This clinical trial is focused on providing extended treatment with ibrutinib for individuals who have previously participated in ibrutinib clinical trials and continue to benefit from its use. Ibrutinib is a medication used in the treatment of various conditions, including Follicular Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Multiple Myeloma, Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, Urothelial Carcinoma, Breast Cancer, Acute Myeloid Leukemia, Graft vs Host Disease, and Mantle Cell Lymphoma. The purpose of this study is to allow patients who have shown positive results from previous trials to continue receiving ibrutinib, even if it is not commercially available in their region.
Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.



Czechia
France
Hungary
Italy
Poland
Spain
Sweden